- Home
- SPAI vs CRDF Comparison
SPAI vs CRDF Comparison
Compare SPAI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPAI | CRDF |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 67.1M |
| IPO Year | 2024 | 2012 |
Fundamental Metrics
Financial Performance| Metric | SPAI | CRDF |
|---|---|---|
| Price | $3.28 | $0.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $10.67 | $6.28 |
| AVG Volume (30 Days) | 117.0K | ★ 389.9K |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,681.00 | $365,993.00 |
| Revenue This Year | $1,156.82 | N/A |
| Revenue Next Year | $143.48 | $8.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $2.75 | $0.75 |
| 52 Week High | $6.70 | $3.31 |
Technical Indicators
Market Signals| Indicator | SPAI | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 35.05 |
| Support Level | $3.11 | $0.77 |
| Resistance Level | $3.53 | $1.47 |
| Average True Range (ATR) | 0.23 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 73.08 | 17.91 |
Price Performance
Historical ComparisonAbout SPAI Safe Pro Group Inc.
Safe Pro Group Inc operates to acquire security and protection products. The company operated in three reportable business segments, which consisted of the business of Safe-Pro USA, the business of Airborne Response, and the business of Safe Pro AI. The majority of revenue is from Safe-Pro USA.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.